Compare SVRA & STK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SVRA | STK |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 921.0M |
| IPO Year | 2009 | 2009 |
| Metric | SVRA | STK |
|---|---|---|
| Price | $4.90 | $50.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $11.06 | N/A |
| AVG Volume (30 Days) | ★ 2.7M | 42.7K |
| Earning Date | 11-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9,266.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.13 | $32.50 |
| 52 Week High | $7.01 | $58.46 |
| Indicator | SVRA | STK |
|---|---|---|
| Relative Strength Index (RSI) | 49.75 | 47.42 |
| Support Level | $4.73 | $50.67 |
| Resistance Level | $5.47 | $53.92 |
| Average True Range (ATR) | 0.32 | 1.63 |
| MACD | 0.04 | -0.14 |
| Stochastic Oscillator | 61.07 | 46.74 |
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services.